PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke

Launched by LUDWIG-MAXIMILIANS - UNIVERSITY OF MUNICH · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a blood marker called Brain-derived tau (BD-tau) to understand how it changes in people who have experienced an acute ischemic stroke. The researchers believe that BD-tau can give important information about brain injury right after a stroke happens. They want to see how quickly BD-tau levels rise and how long they stay elevated, which could help predict recovery outcomes for patients.

To participate in this trial, individuals must be at least 18 years old and have a recent diagnosis of acute ischemic stroke, specifically within 9 hours of the first symptoms. They should also have certain types of blockages in their blood vessels confirmed by imaging tests like CT or MRI. Participants will have their blood tested for BD-tau every hour for the first 48 hours after they arrive at the hospital. This study is currently recruiting participants and aims to gather more insights that could improve stroke care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • clinical diagnosis of acute ischemic stroke
• • presentation within 9 hours of symptom onset
• • large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \[segments M1-M4\], ACA \[segments A1-A3\], basilar artery, or PCA \[segments P1 to P3\]) confirmed by CT or MRI angiography
• • at least 18 years of age
• • written informed consent
• Exclusion Criteria:
• • CT or MRI showing intracranial hemorrhage upon admission
• • A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months
• • severe renal dysfunction (eGFR \< 30ml/min/1.73m2)
• • dementia
• • pre-stroke disability defined as a premorbid modified Rankin Scale score \> 1